Skip to main content

Table 1 Demographic data of 54 juvenile myasthenia gravis patients with different levels of AchR Ab

From: Correlation of anti-acetylcholine receptor antibody levels and long-term outcomes of juvenile myasthenia gravis in Taiwan: a case control study

 

Anti-AchR Ab titer < 0.2 nmol/L (n = 15)

Anti-AchR Ab titer ≥0.2 and <  0.5 nmol/L (n = 8)

Anti-AchR Ab titer ≥0.5 nmol/L (n = 31)

p

n (%)

n (%)

n (%)

 

Sex

Female

7 (46)

4 (50)

19 (61)

0.69

Male

8 (54)

4 (50)

12 (39)

 

Age

< 10 year

8 (53)

6 (75)

22 (71)

0.52

11~20 year

7 (46)

2 (25)

9 (29)

 

Symptoms at onset

Ptosis

15 (100)

8 (100)

29 (94)

1.00

Diurnal change

10 (67)

4 (50)

19 (61)

0.80

Diplopia

5 (33)

2 (25)

4 (13)

0.44

Bulbar sign

3 (23)

0 (0)

5 (19)

0.73

Respiratory symptoms

1 (7)

0 (0)

3 (11)

1.00

Clinical subtype

Ocular type

10 (67)

8 (100)

24 (77)

0.22

Generalized type

5 (33)

0 (0)

7 (23)

 

aMGFA classification

   

0.41

I

10 (67)

8 (100)

24 (77)

 

II

4 (27)

0 (0)

3 (10)

 

III

1 (6)

0 (0)

1 (3)

 

IV

0 (0)

0 (0)

3 (10)

 

V

0 (0)

0 (0)

0

 

Ethnicity

Chinese

15 (100)

8 (100)

31 (100)

1.00

Co-morbid diseases

Thymus hyperplasia

6 (40)

3 (37.5)

10 (32)

0.89

Hyperthyroidism

1 (6.7)

1 (13)

6 (19)

0.66

Thymoma

0

0

1 (3)

NA

Treatment

Total

14 (93)

8 (100)

31 (100)

0.42

Thymectomy

2 (13)

2 (25)

7 (23)

0.71

Prednisolone only

1 (6.7)

0

2 (6.5)

1.00

Anti-cholinergic regimen only

6 (40)

4 (50)

7 (23)

0.23

Both prednisolone and anti-cholinergic regimen

5 (33)

2 (25)

15 (48)

0.44

  1. Abbreviations: Anti-AchR Ab, anti-acetylcholine receptor antibody
  2. aClass I, ocular MG and all other muscle strength is normal; Class II, mild weakness affecting other than ocular muscles; Class III, moderate weakness affecting other than ocular muscles; Class IV, severe weakness affecting other than ocular muscles; Class V, intubation, with or without mechanical ventilation